Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Shenzhen Salubris Pharmaceuticals Co Ltd to Set up Joint Venture
Shenzhen Salubris Pharmaceuticals Co Ltd announced that it will invest RMB 1.5 million to set up a joint venture with a Shanghai-based pharmaceutical company, with each to hold a 50% stake and a 50% stake. The joint venture will be with a registered capital of RMB 3 million and be engaged in the patent asset management.
Latest Developments for Shenzhen Salubris Pharmaceuticals Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd Announces FY 2012 Dividend Payment
- Shenzhen Salubris Pharmaceuticals Co Ltd Announces Change of Accounting Auditor
- Shenzhen Salubris Pharmaceuticals Co Ltd to Set up Joint Venture
- Shenzhen Salubris Pharmaceuticals Co Ltd Announces FY 2012 Net Profit Outlook, Above I/B/E/S Estimates
Latest Key Developments in Pharmaceuticals
- Tonghua Golden-Horse Pharmaceutical Industry Co Ltd Announces Changes of General Manager
- Merck & Co Inc Announces $5 Billion Accelerated Share Repurchase
- Herbalife Ltd Engages PricewaterhouseCoopers LLP As Auditors
- Drug regulator to probe Ranbaxy Laboratories Ltd's records, approvals in India-Business Standard
- Share this
- Link this
- Digg this
Follow Reuters